Novacyt SA (ALNOV) Stock Price & News

Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia

About Novacyt SA

CEODavid Allmond

Employees228

FoundedJul 3, 2006

Headquarters-

SectorHealth Care

IndustryBiotechnology

Websitenovacyt.com

All values in GBP	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	5.12M	5.12M	5.78M	5.78M
Cost of goods sold	2.61M	2.61M	2.56M	2.56M
Cost of revenue	2.61M	2.61M	2.56M	2.56M
Research and development expenses	1.03M	1.03M	1.06M	1.06M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	4.69M	4.69M	4.65M	4.65M
Operating expense	5.54M	5.54M	5.66M	5.66M
Total operating expenses	8.16M	8.16M	8.22M	8.22M
Operating income	-3.04M	-3.04M	-2.44M	-2.44M
Other non operating income	-23.00K	-23.00K	-47.50K	-47.50K
EBT including unusual items	-10.16M	-10.16M	-2.91M	-2.91M
EBT excluding unusual items	-2.52M	-2.52M	-2.80M	-2.80M
Income tax expense	-1.81M	-1.81M	-49.50K	-49.50K
Effective tax rate	17.85%	17.85%	1.70%	1.70%
Other operating expenses	-180.50K	-180.50K	-44.00K	-44.00K
Net income	-8.27M	-8.27M	-2.90M	-2.90M
Net profit margin	-161.60%	-161.60%	-50.13%	-50.13%
Earnings per share	-	-	-	-
Interest and investment income	149.00K	149.00K	63.00K	63.00K
Interest expense	-146.00K	-146.00K	-139.00K	-139.00K
Net interest expenses	3.00K	3.00K	-76.00K	-76.00K
Depreciation and amortization charges	-	-	-	-
EBITDA	3.46M	3.46M	-1.88M	-1.88M
Gain or loss from assets sale	-3.00K	-3.00K	8.00K	8.00K

Finance

Ask anything